Exhibit 99.1 TFF Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update Growing Body of Clinical Data from Ongoing Phase 2 Trial Suggests that Tacrolimus Inhalation Powder (TFF TAC) Could Represent an Important New Innovation for Optimizing Immunosuppressive Therapy in Lung Transplant Recipients Raised $6.0 Million to Support Continued Advancement of TFF TAC into Potentially Registrational Testing Company expects to receive feedback from FDA in Second Quarter Regarding TFF TAC ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the Quarterly Period Ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________to______________________ FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-39102 TFF PHARMACEUTICALS, Inc. (Exact name of registrant as specified in its charter) | Delaware | | ...

Exhibit 99.1 TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results "Over the last several months, we have made significant progress showing that our Thin Film Freezing technology can be successfully applied, with both TFF TAC and TFF VORI demonstrating the potential to significantly improve the product profiles for two FDA- approved therapies," said Harlan Weisman, M.D., Chief Executive Officer of TFF Pharmaceuticals. "As recently announced, we made the decision to prioritize the c ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number: 001-39102 TFF Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) | Delaware | 82-4344737 | | --- | --- | ...

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Corey Davis - IR, LifeSci Advisors Harlan Weisman - CEO Zamaneh Mikhak - Chief Medical Officer Kirk Coleman - CFO Conference Call Participants Jonathan Aschoff - ROTH MKM Justin Walsh - JonesTrading Daniel Carlson - Tailwinds Operator Good afternoon, ladies and gentlemen, and welcome to the TFF Pharmaceuticals Third Quarter 2023 Corporate Update and Earnings Conference Call. As a remind ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________to______________________ Commission file number: 001-39102 TFF PHARMACEUTICALS, INC. (I.R.S. Employer Identification no.) 1751 River Run, Suite 400 Fo ...

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) Q2 2023 Results Conference Call August 15, 2023 11:00 AM ET Company Participants Corey Davis - IR, LifeSci Advisors Dr. Harlan Weisman - CEO Dr. Zamaneh Mikhak - Chief Medical Officer Kirk Coleman - CFO Conference Call Participants Jonathan Aschoff - ROTH MKM Justin Walsh - JonesTrading Vernon Bernardino - H.C. Wainwright Daniel Carlson - Tailwinds Operator Good morning, ladies and gentlemen, and welcome to the TFF Pharmaceuticals Second Quarter 2023 Corporate Update ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________to______________________ Commission file number: 001-39102 (Former name, former address and former fiscal year, if changed since last report) TFF PHARMACEU ...

Safe Harbor Statement • our future financial and operating results; • our intentions, expectations and beliefs regarding anticipated growth, market penetration and trends in our business; • the timing and success of our plan of commercialization; • our ability to successfully develop and clinically test our product candidates; and • our ability to file for FDA approval of our product candidates through the 505(b)(2)regulatory pathway. 2 2 | --- | --- | --- | --- | --- | --- | |------------------------------ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________to______________________ Commission file number: 001-39102 TFF PHARMACEUTICALS, Inc. (Exact name of registrant as specified in its charter) | Delaware | | ...